be detected and better understood via molecular biomarkers such as mRNA. Wren uses qPCR to amplify and identify mRNA biomarkers within a patient's venous blood. Wren then employs AI and machine learning to construct a proprietary suite of algorithms utilizing anonymized patient data from over the last two decades and to then identify potential molecular signatures, cross-referencing them with clinical and scientific data. The results of Wren's diagnostics are unparalleled for their accuracy, sensitivity, and specificity. In addition to our flagship diagnostic for neuroendocrine cancer (the NETest) and the companion PPQ diagnostic which serves as a predictor for the effectiveness of PRRT, Wren has used their scientific platform to develop a saliva-based COVID-19 test that is unsurpassed in both accuracy and sensitivity. Pipeline Investigational Use diagnostics include a prostate cancer diagnostic (PROSTest) as well as other research only diagnostics.